Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKD3 | O94806 | 2/20 | 0.49 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.49 |
| ▸ | RET | P07949 | 2/20 | 0.49 |
| ▸ | PIM1 | P11309 | 2/20 | 0.49 |
| ▸ | KDR | P35968 | 2/20 | 0.49 |
| ▸ | GSK3A | P49840 | 2/20 | 0.49 |
| ▸ | GSK3B | P49841 | 2/20 | 0.49 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.49 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.49 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 0.49 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.49 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.49 |
| ▸ | PLK4 | O00444 | 1/20 | 0.49 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.49 |
| ▸ | CDK1 | P06493 | 1/20 | 0.49 |
| ▸ | LYN | P07948 | 1/20 | 0.49 |
| ▸ | FER | P16591 | 1/20 | 0.49 |
| ▸ | CDK2 | P24941 | 1/20 | 0.49 |
| ▸ | MARK3 | P27448 | 1/20 | 0.49 |
| ▸ | FLT4 | P35916 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29480586 | 1.00 | PRKD3 (0.49) | PRKD3MAP4K4RETPIM1KDR | |
| Hydrochloric Acid SCHEMBL30594385 | 0.98 | PRKD3 (0.47) | PRKD3MAP4K4RETPIM1KDR | |
| Hydrochloric Acid SCHEMBL30775701 | 0.98 | PRKD3 (0.47) | PRKD3MAP4K4RETPIM1KDR | |
| SCHEMBL2121736 | 0.92 | PRKD3 (0.44) | PRKD3MAP4K4RETPIM1KDR | |
| Biphenyl SCHEMBL28782742 | 0.91 | GSK3A (0.63) | PRKD3MAP4K4RETPIM1KDR | |
| SCHEMBL4849645 | 0.86 | PDE3B (0.45) | PRKD3MAP4K4RETPIM1KDR | |
| SCHEMBL360425 | 0.83 | PARP1 (0.55) | PDE3BPDE3APARP1AURKADAO | |
| SCHEMBL4784667 | 0.76 | PARP1 (0.49) | AURKBPDE3BPDE3APARP1AURKA | |
| SCHEMBL1441934 | 0.75 | PARP1 (0.67) | KDRGSK3BCDK5AURKBCDK1 | |
| SCHEMBL66937 | 0.75 | PARP1 (0.58) | PDE3BPDE3APARP1DAOPDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 487 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250066318-A1 | HETEROCYCLIC COMPOUNDS AS DYRK1A INHIBITORS | PROTHENA BIOSCIENCES INC | 2025-02-27 | — | — | US | claimed |
| US-20240343733-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF IRAK4 PROTEINS | C4 THERAPEUTICS, INC. | 2024-10-17 | — | — | US | claimed |
| EP-4367113-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF IRAK4 PROTEINS | Biogen MA Inc. (US) | 2024-05-15 | — | — | EP | claimed |
| CN-117940414-A | Compounds for targeting IRAK4 protein degradation | 渤健马萨诸塞州股份有限公司 | 2024-04-26 | — | — | CN | claimed |
| WO-2023107714-A2 | METHODS FOR TREATING NEUROLOGICAL DISORDERS | PROTHENA BIOSCIENCES LIMITED (IE) | 2023-06-15 | — | — | WO | claimed |
| EP-3523311-B1 | SUBSTITUTED 1H-IMIDAZO[4,5-B]PYRIDIN-2(3H)-ONES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-07 | — | — | EP | claimed |
| WO-2023283610-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF IRAK4 PROTEINS | BIOGEN MA INC. (US) | 2023-01-12 | — | — | WO | claimed |
| US-20230000833-A1 | SUBSTITUTED 1H-IMIDAZO[4,5-b]PYRIDIN-2(3H)-ONES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-01-05 | — | — | US | claimed |
| US-20220235046-A1 | NOVEL COMPOUNDS FOR INHIBITION OF JANUS KINASE 1 | MANKIND PHARMA LTD. (IN) | 2022-07-28 | — | — | US | claimed |
| US-11365205-B2 | Imidazolidin-2-one compounds as PRMT5 modulators | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2022-06-21 | — | — | US | claimed |
| US-7202251-B2 | Bicyclic anilide spirohydantoin CGRP receptor antagonists | MERCK & CO., INC. (US) | 2007-04-10 | — | — | US | claimed |
| EP-1740185-A1 | BENZODIAZEPINES FOR TREATING OR PREVENTING RSV INFECTION | Arrow Therapeutics Limited (GB) | 2007-01-10 | — | — | EP | claimed |
| EP-1727551-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A BENZODIAZEPINE DERIVATIVE AND A INHIBITOR OF THE RSV FUSION PROTEIN | Arrow Therapeutics Limited (GB) | 2006-12-06 | — | — | EP | claimed |
| US-20060211712-A1 | Bicyclic anilide spirohydantoin cgrp receptor antagonists | MERCK SHARP & DOHME LLC | 2006-09-21 | — | — | US | claimed |
| WO-2005089770-A1 | BENZODIAZEPINES FOR TREATING OR PREVENTING OR PREVENTING RSV INFECTION | ARROW THERAPEUTICS LIMITED (GB) | 2005-09-29 | — | — | WO | claimed |
| WO-2005089771-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A BENZODIAZEPINE DERIVATIVE AND A INHIBITOR OF THE RSV FUSION PROTEIN | ARROW THERAPEUTICS LIMITED (GB) | 2005-09-29 | — | — | WO | claimed |
| EP-0767782-B1 | ARYL AND HETEROARYL ALKOXYNAPHTHALENE DERIVATIVES | PFIZER (US) | 2001-10-31 | — | — | EP | claimed |
| EP-0795328-A1 | Use of naphthalene derivatives in treating lung carcinoma | PFIZER INC. (US) | 1997-09-17 | — | — | EP | claimed |
| US-4806560-A | ANTIHISTAMINES AND ANTISEROTONINE AGENTS | SYNTHELABO (FR) | 1989-02-21 | — | — | US | claimed |
| US-4256819-A | MEROCYANINES | EASTMAN KODAK COMPANY (US) | 1981-03-17 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250066318-A1 | HETEROCYCLIC COMPOUNDS AS DYRK1A INHIBITORS | DYRK1A, DYRK2, DYRK1B | PRKD3 262/4885MAP4K4 119/4885RET 134/4885 |
| US-11365205-B2 | Imidazolidin-2-one compounds as PRMT5 modulators | PRMT5, PRMT1, PRMT7 | PRKD3 699/4885MAP4K4 1173/4885RET 527/4885 |
| US-20230000833-A1 | SUBSTITUTED 1H-IMIDAZO[4,5-b]PYRIDIN-2(3H)-ONES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | GRIN2B, GRIN2A, GRIN2C | PRKD3 2794/4885MAP4K4 1223/4885RET 512/4885 |
| US-20060211712-A1 | Bicyclic anilide spirohydantoin cgrp receptor antagonists | BDKRB2, CALCRL, CCKBR | PRKD3 3298/4885MAP4K4 3862/4885RET 1946/4885 |
| US-20220235046-A1 | NOVEL COMPOUNDS FOR INHIBITION OF JANUS KINASE 1 | JAK1, JAK2, JAK3 | PRKD3 276/4885MAP4K4 78/4885RET 440/4885 |
| US-20240343733-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF IRAK4 PROTEINS | IRAK4, IRAK2, IRAK1 | PRKD3 370/4885MAP4K4 414/4885RET 1139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.